Ghost cell glaucoma after intravitreal bevacizumab for postoperative vitreous hemorrhage following vitrectomy for proliferative diabetic retinopathy

Laura Liu, Wei Chi Wu, Ling Yeung, Nan Kai Wang, Ya Hui Kuo, An Ning Chao, Kuan Jen Chen, Tun Lu Chen, Chi Chun Lai*, Yih Shiou Hwang, Yen Po Chen

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

12 Scopus citations

Abstract

■ BACKGROUND AND OBJECTIVE: To report the occurrence of ghost cell glaucoma after intravitreal injection of bevacizumab for the treatment of postoperative vitreous hemorrhage after vitrectomy for proliferative diabetic retinopathy (PDR). ■ PATIENTS AND METHODS: Retrospective chart review from August 2006 to December 2007. Patients who had postoperative vitreous hemorrhage after vitrectomy for PDR and received an intravitreal injection of bevacizumab were enrolled in the study. ■ RESULTS: Eight eyes of 8 patients (mean age: 46 years) were included. After intravitreal injection of bevacizumab, 4 (50%) eyes had clearance of vitreous hemorrhage. Three eyes developed ghost cell glaucoma within 1 week after intravitreal injection of bevacizumab. Of these, intraocular pressure was controlled in 1 eye through the use of anti-glaucoma medication, whereas the other 2 eyes needed surgical intervention to lower intraocular pressure and subsequently clear the vitreous hemorrhage. ■ CONCLUSION: Intravitreal injection of bevacizumab may accelerate the clearance of postoperative vitreous hemorrhage in cases of PDR. However, a high incidence of ghost cell glaucoma was observed. Caution should be exercised when administering an intravitreal injection of bevacizumab for a postoperative vitreous hemorrhage after vitrectomy for PDR.

Original languageEnglish
Pages (from-to)72-77
Number of pages6
JournalOphthalmic Surgery Lasers and Imaging
Volume41
Issue number1
DOIs
StatePublished - 01 2010

Fingerprint

Dive into the research topics of 'Ghost cell glaucoma after intravitreal bevacizumab for postoperative vitreous hemorrhage following vitrectomy for proliferative diabetic retinopathy'. Together they form a unique fingerprint.

Cite this